Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Only 1.45%
Wall Street's Current Play: 'Immunotherapy Of Cancer' $PPHM
http://www.seekingalpha.com/article/2953756
Bad news. We will never see $5 again
800.000????
What???
And why PPHM is going down?.
What happen????
I think The managers are playing with us.
-
-
-
Down and down and down
The form 10?. When?.
No, it is not.
200 ask jijiji
PR???. Where?.
This company is a big disaster
Go and gow down again
What is Mad Money?.
It was time to sell at 1.57. PPHM is going down to 1.40 again in few minutes
Time to sell?.
Going down again
Year 2015 = year 2014. We have to wait til 2016
Just +14%?.
Interesting day?.
Why 1.50??
Down and down in the new year.
Credibility is zero.
Do you know this bullshit company?.
SGOC is a great bullshit company.
Yes. ?
Fucking company!!!!
Great day
8:01 am Peregrine Pharma announces preclinical data from recently conducted single agent studies; statistically significant tumor growth suppression with single agent Bavituximab equivalent (PPHM) : Co announces preclinical data from recently conducted single agent studies at the 2014 San Antonio Breast Cancer Symposium held December 9-13. Newly published data show that ch1N11, the preclinical equivalent to bavituximab, as a single agent, demonstrated statistically significant (p=0.025) tumor growth inhibition in mice bearing EMT-6 breast tumors when compared to a control antibody. In addition, researchers using fluorescence-activated cell sorting (:FACS) found that the single agent treatment of tumor bearing mice with ch1N11 yielded statistically significant increases in the percentage of CD4 (p=0.016) and CD8 (p=0.018) tumor infiltrating lymphocytes and decreases tumor MDSC/CD4 (p=0.026) and MDSC/CD8 (p=0.014) ratios, all key indicators of stimulating immune activation.
Peregrine Pharmaceuticals to Report Second Quarter Fiscal 2015 Financial Results After Market on December 10, 2014
We have lost our money. I think it is enough.
0.00000000000000000000000001
Peregrine reports December 10
Yesterday, 04:26 PM ET · PPHM
Peregrine Pharmaceuticals (NASDAQ:PPHM) will report fiscal Q2 results on December 10 after the close. The conference call will begin at 1:30 pm PT/4:30 pm ET.
Consensus view is a loss of ($0.07) on revenues of $5.8M.
This company will never go up until the values of the old ATRN.
how can any company justify $1.38 now?.
Yessssss
Earnings when?.